EUZ Stock Overview
Through its subsidiaries, manufactures and sells isotope technology components for medical, scientific, and industrial applications worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
Rewards
Risk Analysis
No risks detected for EUZ from our risk checks.
Eckert & Ziegler SE Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €44.80 |
| 52 Week High | €0 |
| 52 Week Low | €0 |
| Beta | 1.22 |
| 11 Month Change | -2.71% |
| 3 Month Change | 20.37% |
| 1 Year Change | 22.77% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -53.47% |
Recent News & Updates
Recent updates
Shareholder Returns
| EUZ | BG Medical Equipment | BG Market | |
|---|---|---|---|
| 7D | -0.4% | -0.5% | -0.7% |
| 1Y | 22.8% | 6.8% | 19.0% |
Return vs Industry: EUZ exceeded the BG Medical Equipment industry which returned 6.8% over the past year.
Return vs Market: EUZ exceeded the BG Market which returned 19% over the past year.
Price Volatility
| EUZ volatility | |
|---|---|
| EUZ Average Weekly Movement | 5.8% |
| Medical Equipment Industry Average Movement | 5.6% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in BG Market | 8.3% |
| 10% least volatile stocks in BG Market | 2.1% |
Stable Share Price: EUZ's share price has been volatile over the past 3 months.
Volatility Over Time: EUZ's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1992 | 1,072 | Harald Hasselmann | www.ezag.com |
Eckert & Ziegler SE, through its subsidiaries, manufactures and sells isotope technology components for medical, scientific, and industrial applications worldwide. It operates in two segments, Medical and Isotope Products. The Medical segment offers small radioactive implants for the treatment of prostate cancer seeds; and eye application based on ruthenium-106 or iodine-125 for treating uveal melanoma.
Eckert & Ziegler SE Fundamentals Summary
| EUZ fundamental statistics | |
|---|---|
| Market cap | €938.05m |
| Earnings (TTM) | €33.87m |
| Revenue (TTM) | €255.78m |
27.7x
P/E Ratio3.7x
P/S RatioIs EUZ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EUZ income statement (TTM) | |
|---|---|
| Revenue | €255.78m |
| Cost of Revenue | €131.99m |
| Gross Profit | €123.79m |
| Other Expenses | €89.91m |
| Earnings | €33.87m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 09, 2024
| Earnings per share (EPS) | 1.63 |
| Gross Margin | 48.40% |
| Net Profit Margin | 13.24% |
| Debt/Equity Ratio | 10.6% |
How did EUZ perform over the long term?
See historical performance and comparison